Langerhans cell Histiocytosis (LCH) is a rare disease for which treatment with 2- chlorodeoxyadenosine (cladribine) has changed disease outcome. Cladribine has meanwhile been administered over two decades and is available for intravenous and subcutaneous administration. Cladribine has been administered in treatment of therapy naïve, relapsed and refractory LCH and induces high response rates, regardless of prior treatment. Literature describing the use of cladribine either alone or in combination with cytarabine is summarized herein.
Marlies E.H.M. van Hoef
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : April 20, 2019